Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis

Abstract : AbstractDeregulated expression of heat shock proteins (HSPs) encoding genes is frequent in multiple myeloma. HSPs, which are molecular chaperones involved in protein homeostasis pathways, have emerged recently as promising therapeutic targets. Using human myeloma cell lines and primary myeloma cells belonging to various molecular groups, we tested the efficacy of HSP90, HSP70, and heat shock factor 1 (HSF1) inhibitors alone or associated with current antimyeloma drugs. We report here that KNK-437 (an inhibitor of HSF1) and bortezomib have additive effects on apoptosis induction in cells belonging to groups with bad prognosis.
Type de document :
Article dans une revue
Journal of Hematology & Oncology, 2015, 8 (1), pp.40. 〈10.1186/s13045-015-0135-3〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01237704
Contributeur : Bmc Bmc <>
Soumis le : jeudi 3 décembre 2015 - 16:15:50
Dernière modification le : mardi 5 juin 2018 - 10:14:43
Document(s) archivé(s) le : samedi 29 avril 2017 - 05:14:06

Fichiers

13045_2015_Article_135.pdf
Publication financée par une institution

Identifiants

Collections

Citation

Sophie Bustany, Julie Cahu, Géraldine Descamps, Catherine Pellat-Deceunynck, Brigitte Sola. Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis. Journal of Hematology & Oncology, 2015, 8 (1), pp.40. 〈10.1186/s13045-015-0135-3〉. 〈inserm-01237704〉

Partager

Métriques

Consultations de la notice

251

Téléchargements de fichiers

48